Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
BIORA THERAPEUTICS, INC. (PROG)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues: |
| Revenue from Discontinued Operations | | | 9.9 | | | 7.2 | 9.5 | 18.2 |
| Total revenues | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.4 | 0.2 | 0.5 |
| Revenue growth [+] | -98.1% | -98.1% | -56.0% | -77.5% | -35.9% | 310.4% | 225.0% | -97.3% |
| Revenue from Discontinued Operations | | | 4.1% | | | -49.0% | -63.2% | 5.7% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.4 | 0.2 | 0.5 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative [+] | 14.9 | 15.5 | 14.0 | 14.3 | 20.0 | 0.3 | 30.7 | 36.1 |
| Sales and marketing | | | | | | 0.3 | | |
| Research and development | | | | | | | | |
| Other operating expenses | 2.7 | 2.8 | 3.0 | -8.7 | 4.4 | 46.9 | 2.5 | -2.3 |
| EBITDA [+] | -17.5 | -18.2 | -16.7 | -5.3 | -24.0 | -46.4 | -33.0 | -32.8 |
| EBITDA growth | 230.6% | -23.9% | -49.5% | -83.9% | 400.1% | -34.4% | 0.3% | -3.4% |
| EBITDA margin | -874050.0% | -911950.0% | -20822.5% | -5083.7% | -22400.0% | -10669.9% | -18124.2% | -7091.4% |
| Depreciation | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 | 0.4 | 0.1 | 0.2 |
| EBITA | -17.6 | -18.4 | -16.9 | -5.5 | -24.3 | -46.8 | -33.1 | -33.1 |
| EBITA margin | -882350.0% | -919300.0% | -21075.0% | -5300.0% | -22700.9% | -10755.6% | -18178.6% | -7138.9% |
| Amortization of intangibles | | | | | | | | 0.3 |
| EBIT [+] | -17.6 | -18.4 | -16.9 | -5.5 | -24.3 | -46.8 | -33.1 | -33.4 |
| EBIT growth | 220.2% | -24.3% | -49.0% | -83.5% | 363.7% | -34.2% | -0.2% | -8.6% |
| EBIT margin | -882350.0% | -919300.0% | -21075.0% | -5300.0% | -22700.9% | -10755.6% | -18178.6% | -7203.7% |
| Interest expense | | | | | | | | |
| Interest expense | 2.7 | 2.7 | 2.8 | 2.8 | 2.8 | 2.2 | 3.5 | 3.5 |
| Other income (expense), net | 2.5 | 3.6 | 4.9 | 1.5 | 12.6 | -33.9 | -0.3 | -4.5 |
| Pre-tax income | -17.8 | -17.4 | -14.7 | -6.8 | -14.5 | -82.9 | -36.9 | -41.4 |
| Income taxes | 0.0 | 0.0 | 0.2 | -0.8 | -0.7 | -58.9 | 0.0 | 0.0 |
| Tax rate | | 0.0% | | 12.2% | 4.7% | 71.1% | 0.0% | 0.0% |
| Net income | -17.8 | -17.4 | -5.1 | -5.5 | -13.8 | -92.9 | -43.7 | -78.5 |
| Net margin | -890350.0% | -872050.0% | -6392.5% | -5301.0% | -12904.7% | -21350.1% | -24035.2% | -16961.3% |
| |
| Basic EPS [+] | ($1.47) | ($1.59) | ($0.08) | ($0.81) | ($1.98) | ($0.86) | ($0.38) | ($0.65) |
| Growth | 80.3% | -19.6% | -79.3% | 25.6% | 551.1% | -52.6% | -45.9% | -82.8% |
| Diluted EPS [+] | ($1.47) | ($1.59) | ($0.08) | ($0.81) | ($1.98) | ($0.86) | ($0.38) | ($0.65) |
| Growth | 80.3% | -19.6% | -79.3% | 25.6% | 551.1% | -52.6% | -45.9% | -82.8% |
| |
| |
| Shares outstanding (basic) [+] | 12.1 | 11.0 | 187.0 | 7.4 | 7.3 | 96.2 | 95.8 | 63.9 |
| Growth | 64.7% | 49.7% | 95.1% | -88.5% | -87.3% | 249.5% | 105.5% | 636.0% |
| Shares outstanding (diluted) [+] | 12.1 | 11.0 | 187.0 | 7.4 | 7.3 | 96.2 | 95.8 | 63.9 |
| Growth | 64.7% | 49.7% | 95.1% | -88.5% | -87.3% | 249.5% | 105.5% | 636.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|